Ginkgo biloba Extract 50 (GBE50) Ameliorates Insulin Resistance, Hepatic Steatosis and Liver Injury in High Fat Diet-Fed Mice

References

• Sookoian S, Pirola CJ, Chan C. Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease. PLoS One. 2013;8(3):e58895. doi:10.1371/journal.pone.0058895
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15(1):45. doi:10.1186/s12916-017-0806-8
   PubMed Web of Science ®Google Scholar
• Zhao ZY, Liu D, Cao WJ, et al. Association between IgG N-glycans and nonalcoholic fatty liver disease in Han Chinese. Biomed Environ Sci. 2018;31(6):454–458. doi:10.3967/bes2018.059
   PubMed Web of Science ®Google Scholar
• Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Nonalcoholic fatty liver disease: evolving paradigms. World J Gastroenterol. 2017;23:6571–6592. doi:10.3748/wjg.v23.i36.6571
   PubMed Web of Science ®Google Scholar
• Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol. 2019;70(3):531–544. doi:10.1016/j.jhep.2018.10.033
   PubMed Web of Science ®Google Scholar
• Kim JY, Cho J, Yang HR. Biochemical predictors of early onset non-alcoholic fatty liver disease in young children with obesity. J Korean Med Sci. 2018;33(16):e122. doi:10.3346/jkms.2018.33.e122
   PubMed Web of Science ®Google Scholar
• Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23:8263–8276. doi:10.3748/wjg.v23.i47.8263
   PubMed Web of Science ®Google Scholar
• Hartmann P, Schnabl B. Risk factors for progression of and treatment options for NAFLD in children. Clin Liver Dis (Hoboken). 2018;11(1):11–15. doi:10.1002/cld.685
   PubMedGoogle Scholar
• Cole BK, Feaver RE, Wamhoff BR, Dash A. Non-alcoholic fatty liver disease (NAFLD) models in drug discovery. Expert Opin Drug Discov. 2018;13(2):193–205. doi:10.1080/17460441.2018.1410135
   PubMed Web of Science ®Google Scholar
• Manne V, Handa P, Kowdley KV. Pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Clin Liver Dis. 2018;22(1):23–37. doi:10.1016/j.cld.2017.08.007
   PubMed Web of Science ®Google Scholar
• Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76(1):99–128.
   PubMed Web of Science ®Google Scholar
• Lu S, Guo X, Zhao P. Effect of Ginkgo biloba extract 50 on immunity and antioxidant enzyme activities in ischemia reperfusion rats. Molecules. 2011;16(11):9194–9206. doi:10.3390/molecules16119194
   PubMed Web of Science ®Google Scholar
• He GY, Yuan CG, Hao L, Xu Y, Zhang ZX. GBE50 attenuates inflammatory response by inhibiting the p38 MAPK and NF-κB pathways in LPS-stimulated microglial cells. Evid Based Complement Alternat Med. 2014;2014:368598. doi:10.1155/2014/368598
   PubMed Web of Science ®Google Scholar
• Han C, Ren Y, Jia Y, Kong L, Eerdun T, Wu L. The effective mode of growth and differentiation factor-5 in promoting the chondrogenic differentiation of adipose-derived stromal cells. Cell Tissue Bank. 2016;17(1):105–115. doi:10.1007/s10561-015-9517-6
   PubMed Web of Science ®Google Scholar
• Huang EW, Xue SJ, Zhang Z, Zhou JG, Guan YY, Tang YB. Vinpocetine inhibits breast cancer cells growth in vitro and in vivo. Apoptosis. 2012;17(10):1120–1130. doi:10.1007/s10495-012-0743-0
   PubMed Web of Science ®Google Scholar
• Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–1048. doi:10.1016/j.metabol.2015.12.012
   PubMed Web of Science ®Google Scholar
• Lebeaupin C, Vallée D, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2018;69(4):927–947. doi:10.1016/j.jhep.2018.06.008
   PubMed Web of Science ®Google Scholar
• Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68(2):280–295. doi:10.1016/j.jhep.2017.11.014
   PubMed Web of Science ®Google Scholar
• Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 2011;54:133–144. doi:10.1002/hep.24341
   PubMed Web of Science ®Google Scholar
• Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112(1):18–35. doi:10.1038/ajg.2016.517
   PubMed Web of Science ®Google Scholar
• Alisi A, Bedogni G, De Vito R, Comparcola D, Manco M, Nobili V. Relationship between portal chronic inflammation and disease severity in paediatric non-alcoholic fatty liver disease. Dig Liver Dis. 2011;43(2):143–146. doi:10.1016/j.dld.2010.05.007
   PubMedGoogle Scholar
• Fan Y, He Z, Wang W, et al. Tangganjian decoction ameliorates type 2 diabetes mellitus and nonalcoholic fatty liver disease in rats by activating the IRS/PI3K/AKT signaling pathway. Biomed Pharmacother. 2018;106:733–737. doi:10.1016/j.biopha.2018.06.089
   PubMed Web of Science ®Google Scholar
• Guo JW, Liu X, Zhang TT, et al. Hepatocyte TMEM16A deletion retards NAFLD progression by ameliorating hepatic glucose metabolic disorder. Adv Sci (Weinh). 2020;7(10):1903657. doi:10.1002/advs.201903657
   PubMedGoogle Scholar
• Wu WY, Yang WZ, Hou JJ, De DA. Current status and future perspective in the globalization of Traditional Chinese Medicines. World J Tradit Chin Med. 2015;1(1):1–4. doi:10.15806/j.issn.2311-8571.2014.0027
   Google Scholar
• Staehr P, Hother-Nielsen O, Landau BR, Chandramouli V, Holst JJ, Beck-Nielsen H. Effects of free fatty acids perse on glucose production, gluconeogenesis, and glycogenolysis. Diabetes. 2003;52:260–267. doi:10.2337/diabetes.52.2.260
   PubMed Web of Science ®Google Scholar
• Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148:852–871. doi:10.1016/j.cell.2012.02.017
   PubMed Web of Science ®Google Scholar
• Shirpoor A, Heshmati E, Kheradmand F, et al. Increased hepatic FAT/CD36, PTP1B and decreased HNF4A expression contributes to dyslipidemia associated with ethanol-induced liver dysfunction: rescue effect of ginger extract. Biomed Pharmacother. 2018;105:144–150. doi:10.1016/j.biopha.2018.05.121
   PubMed Web of Science ®Google Scholar
• Amini M, Saboory E, Pourheydar B, Bagheri M, Naderi R. Involvement of endocannabinoid system, inflammation and apoptosis in diabetes induced liver injury: role of 5-HT3 receptor antagonist. Int Immunopharmacol. 2020;79:106158. doi:10.1016/j.intimp.2019.106158
   PubMed Web of Science ®Google Scholar
• Xu B, Jiang M, Chu Y, et al. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice. J Hepatol. 2018;68(4):773–782. doi:10.1016/j.jhep.2017.11.040
   PubMed Web of Science ®Google Scholar
• Feng D, Zou J, Su D, et al. Curcumin prevents high-fat diet-induced hepatic steatosis in ApoE(-/-) mice by improving intestinal barrier function and reducing endotoxin and liver TLR4/NF-kappaB inflammation. Nutr Metab (Lond). 2019;16:79. doi:10.1186/s12986-019-0410-3
   PubMed Web of Science ®Google Scholar
• Hao YR, Tang FJ, Zhang X, Wang H. Suppression of NF-kappaB activation by PDLIM2 restrains hepatic lipogenesis and inflammation in high fat diet induced mice. Biochem Biophys Res Commun. 2018;503(2):564–571. doi:10.1016/j.bbrc.2018.05.187
   PubMed Web of Science ®Google Scholar
• Copps KD, White MF. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia. 2012;55(10):2565–2582. doi:10.1007/s00125-012-2644-8
   PubMed Web of Science ®Google Scholar
• Sharma RS, Harrison DJ, Kisielewski D, et al. Experimental nonalcoholic steatohepatitis and liver fibrosis are ameliorated by pharmacologic activation of Nrf2 (NF-E2 p45-Related Factor 2). Cell Mol Gastroenterol Hepatol. 2017;5(3):367–398. doi:10.1016/j.jcmgh.2017.11.016
   PubMed Web of Science ®Google Scholar
• Duvigneau JC, Luís A, Gorman AM, et al. Crosstalk between inflammatory mediators and endoplasmic reticulum stress in liver diseases. Cytokine. 2019;124:154577. doi:10.1016/j.cyto.2018.10.018
   PubMed Web of Science ®Google Scholar
• Hassler J, Cao SS, Kaufman RJ. IRE1, a double-edged sword in pre-miRNA slicing and cell death. Dev Cell. 2012;23(5):921–923. doi:10.1016/j.devcel.2012.10.025
   PubMed Web of Science ®Google Scholar
• Lee YS, Lee DH, Choudry HA, Bartlett DL, Lee YJ. Ferroptosis-induced endoplasmic reticulum stress: cross-talk between ferroptosis and apoptosis. Mol Cancer Res. 2018;16(7):1073–1076. doi:10.1158/1541-7786.MCR-18-0055
   PubMed Web of Science ®Google Scholar
• Guo H, Li H, Wang B, et al. Protective effects of glucagon-like peptide-1 analog on renal tubular injury in mice on high-fat diet. Cell Physiol Biochem. 2017;41(3):1113–1124. doi:10.1159/000464118
   PubMedGoogle Scholar
• Hazari YM, Habib M, Bashir S, et al. Natural osmolytes alleviate GRP78 and ATF-4 levels: corroboration for potential modulators of unfolded protein response. Life Sci. 2016;146:148–153. doi:10.1016/j.lfs.2016.01.002
   PubMed Web of Science ®Google Scholar
• Oyadomari S, Harding HP, Zhang Y, Oyadomari M, Ron D. Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice. Cell Metab. 2008;7(6):520–532. doi:10.1016/j.cmet.2008.04.011
   PubMed Web of Science ®Google Scholar
• Enos RT, Velázquez KT, Carson MS, et al. A low dose of dietary quercetin fails to protect against the development of an obese phenotype in mice. PLoS One. 2016;11(12):e0167979. doi:10.1371/journal.pone.0167979
   PubMed Web of Science ®Google Scholar
• Cho EJ, Yoon JH, Kwak MS, et al. Tauroursodeoxycholic acid attenuates progression of steatohepatitis in mice fed a methionine-choline-deficient diet. Dig Dis Sci. 2014;59(7):1461–1474. doi:10.1007/s10620-014-3217-0
   PubMed Web of Science ®Google Scholar
• Nishio N, Isobe K. GADD34-deficient mice develop obesity, nonalcoholic fatty liver disease, hepatic carcinoma and insulin resistance. Sci Rep. 2015;5:13519. doi:10.1038/srep13519
   PubMed Web of Science ®Google Scholar
• Zhang X, Han J, Man K, et al. CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy. J Hepatol. 2016;64(1):160–170. doi:10.1016/j.jhep.2015.09.005
   PubMed Web of Science ®Google Scholar